<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538511</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1638</org_study_id>
    <nct_id>NCT01538511</nct_id>
  </id_info>
  <brief_title>Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers</brief_title>
  <official_title>A Two-centre, Randomised, Open-labelled, Four-week, Parallel-group Pharmacokinetics Trial in Japanese Type 2 Diabetic Subjects Characterising the Insulin Profile of Thrice Daily Regimen With Biphasic Insulin Aspart 70 (NN2000-Mix70) With Reference to That of Twice Daily Regimen With Biphasic Insulin Aspart 30 (NN-X14Mix30) and Physiological Insulin Profile in Japanese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart
      70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30
      (NN-X14Mix30) in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2006</start_date>
  <completion_date type="Actual">March 13, 2007</completion_date>
  <primary_completion_date type="Actual">March 13, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma insulin concentration curve from 0 to 24 hours</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve of plasma insulin from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma insulin concentration observed from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma insulin concentration from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 24-hour plasma insulin profile deviances in Japanese type 2 diabetic subjects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-meal plasma glucose concentration before meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial plasma glucose (PPPG) excursion from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma glucose concentration observed from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach the maximum plasma glucose concentration of observed from 0 to 4 hours after meals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of plasma glucose concentration from 0 to 24 hours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma C-peptide concentration curve from 0 to 24 hours derived from the 24-hour plasma C-peptide profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycaemic episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted</description>
    <arm_group_label>BIAsp 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted</description>
    <arm_group_label>BIAsp 30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        SUBJECTS WITH TYPE 2 DIABETES

          -  Subjects with type 2 diabetes mellitus

          -  Current treatment using intermediate-acting, long-acting or pre-mixed/biphasic insulin
             preparation (including insulin analogues) in once or twice daily (before breakfast and
             dinner) treatment regimen for at least 12 weeks (a temporary use [maximum of one week
             in total] of rapid-acting human insulin will be allowed)

          -  Age between 20-69 years, both inclusive

          -  HbA1c (glycosylated haemoglobin A1c) below 9.0%

          -  Body Mass Index (BMI) 18.5-25.0 kg/m^2

          -  Total daily insulin dose (per day) above 0.2 U or IU/kg body weight and below 1.0 U or
             IU/kg body weight HEALTHY VOLUNTEERS

          -  Japanese subjects with considered generally healthy based on medical history and
             physical examination

          -  Age between 20-29 years, both inclusive

          -  Body Mass Index (BMI) 18.5-25.0 kg/m^2

          -  Subjects with normal glucose tolerance (NGT); defined as fasting plasma glucose below
             110 mg/dL and 2-hour post OGTT (oral glucose tolerance test) plasma glucose below 140
             mg/dL

        Exclusion Criteria:

        SUBJECTS WITH TYPE 2 DIABETES

          -  Proliferative retinopathy or maculopathy requiring acute treatment

          -  Impaired hepatic function

          -  Impaired renal function

          -  Serious cardiac diseases

          -  Uncontrolled hypertension

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia

          -  Current treatment or expected at the screening to start treatment with systemic
             corticosteroids HEALTHY VOLUNTEERS

          -  Any clinical laboratory values deviated from the reference range at the laboratory
             (except for cases within physiological change) at the screening

          -  History or presence of diabetes, cancer or any clinically significant cardiac,
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,
             dermatological, venereal, haematological, neurological, or psychiatric diseases or
             disorders

          -  Subjects with a first-degree relative with diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

